GlassScriptPhysician profile
Ileana Martinez
NPI 1326032913
$7,106.12
in general payments reported to CMS, 2019-2025
33 companies · $1,114 in 2025
The $1,114 reported for 2025 was more than what 80% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $883 · 2020: $574 · 2021: $864 · 2022: $1,098 · 2023: $1,494 · 2024: $1,080 · 2025: $1,114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,462 · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,461.68 |
| Education | $226.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,231.38 | 2019-2025 | Lokelma, Farxiga |
| Vifor Pharma, INC. | $974.55 | 2019-2023 | Veltassa, Korsuva |
| Otsuka America Pharmaceutical, INC. | $544.46 | 2019-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $420.44 | 2021-2025 | |
| Amgen INC. | $399.53 | 2019-2025 | Krystexxa, Tavneos |
| Travere Therapeutics, INC. | $338.36 | 2022-2025 | |
| Opko Pharmaceuticals, LLC | $329.73 | 2019-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $311.02 | 2021-2025 | Benlysta |
| Horizon Therapeutics Plc | $310.65 | 2019-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $285.35 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $240.85 | 2019-2024 | Auryxia, Vafseo |
| Aurinia Pharma U.S., INC. | $238.34 | 2021-2025 | Lupkynis |
| Alexion Pharmaceuticals, INC. | $206.94 | 2019-2024 | Ultomiris |
| Fresenius USA Marketing, INC. | $161.24 | 2023-2025 | Velphoro, Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.76 | 2024-2025 | Jardiance |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $130.84 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $101.91 | 2021-2023 | Gattex |
| Janssen Pharmaceuticals, INC | $94.08 | 2020 | |
| Nxstage Medical, INC. | $81.33 | 2020-2024 | |
| Novartis Pharmaceuticals Corporation | $80.41 | 2023-2024 | |
| Cormedix INC. | $68.72 | 2024 | Defencath |
| Dexcom, INC. | $57.74 | 2023-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $52.23 | 2024 | |
| Lilly USA, LLC | $50.09 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Ultragenyx Pharmaceutical INC. | $42.10 | 2022-2023 | |
| Daiichi Sankyo INC. | $40.51 | 2019 | |
| Veloxis Pharmaceuticals, INC. | $31.90 | 2023 | Envarsus |
| Pfizer INC. | $30.52 | 2019-2022 | |
| Ardelyx, INC. | $25.15 | 2024 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $23.47 | 2021 | |
| Amarin Pharma, INC. | $15.84 | 2019 | |
| Ani Pharmaceuticals, INC. | $15.13 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $14.55 | 2023 | Terlivaz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ileana Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.